Investors warn of persistent funding gaps for university spinouts in Europe

While deeptech commands a larger portion of European early-stage funding than in previous years, university spinouts continue to receive a disproportionately small share of capital. Investors active in the space suggest that venture capital firms are too hesitant to engage with the structural complexities inherent in academic commercialization.

Common obstacles for these companies include protracted negotiations over intellectual property and technical risks that do not align with the standard requirements of venture capital funds. Many investors prioritize companies with more predictable paths to market, effectively sidelining deeptech firms that require longer incubation periods.

Experts argue that the sector needs a shift in strategy. Instead of demanding immediate commercial proof, investors should foster an environment that accommodates longer research and development cycles. Failing to adjust these expectations means that significant technological potential remains trapped within academic institutions.

Ultimately, the disconnect between venture capital risk profiles and the nature of spinout development creates a bottleneck. Addressing these funding gaps is essential for Europe to translate its scientific research into viable, scalable commercial enterprises.